Levocarnil (Levocarnitine)

Levocarnil acts on metabolic pathways that require carnitine for fatty‑acid transport and oxidation.

• Carnitine deficiency: restores normal carnitine levels and improves energy production.
• Secondary carnitine deficiency: compensates for loss of endogenous carnitine due to disease or medication.
• Support of fatty‑acid metabolism: enhances mitochondrial β‑oxidation, aiding patients with metabolic stress.

• Levocarnitine functions as a carrier molecule that transports long‑chain fatty acids across the inner mitochondrial membrane. By forming acyl‑carnitine esters, it enables these fatty acids to enter mitochondria where they undergo β‑oxidation, thereby generating acetyl‑CoA for the citric acid cycle and supporting cellular energy metabolism.

Levocarnil is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Nausea: mild gastrointestinal upset.
• Diarrhea: loose stools, usually transient.
• Abdominal cramps: discomfort in the stomach area.
• Headache: mild to moderate intensity.
• Metallic taste: temporary alteration of taste perception.

Serious or Rare Side Effects

• Hypersensitivity reaction: rash, itching, or swelling.
• Severe abdominal pain: may indicate underlying gastrointestinal issue.
• Muscle weakness: rare, may affect mobility.
• Elevated serum ammonia: uncommon, requires monitoring.
• Cardiac arrhythmia: very rare, especially in patients with pre‑existing heart conditions.

Levocarnil should be used with awareness of specific safety considerations.

• Renal impairment: adjust use as excretion may be reduced.
• Hepatic disease: monitor liver function tests periodically.
• Thyroid disorders: assess thyroid status before initiating therapy.
• Pediatric use: dosage and safety not established for children under 2 years.
• Pregnancy and lactation: consult a healthcare professional before use.
• Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture and direct sunlight.

Levocarnil may interact with certain medicines, requiring attention.

Major Interactions (Avoid)

• Valproic acid: may increase serum ammonia levels.
• Certain antibiotics (e.g., cefoperazone): can reduce carnitine absorption.

Moderate Interactions (Monitor Closely)

• Anticonvulsants (e.g., carbamazepine): may alter carnitine metabolism.
• Dialysis treatments: can remove levocarnitine, necessitating supplemental dosing.
• High‑dose vitamin C: may affect carnitine transport mechanisms.
• Diuretics: increased renal excretion may lower carnitine levels.
• Statins: monitor for muscle-related side effects when combined.